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Abstract

Abstract
Atherosclerosis describes a diseased narrowing of an artery lumen, which untreated can ultimately lead to cardiac
arrest and infarcts, yet difficult to combat. Especially severe stages are treated regularly using bare-metal and nonbioresorbable drug-eluting stents. However, incidence of stent failure is often associated with restenosis and
thrombosis, which is due to their non-degradable nature. Hence, cardiovascular research shifts their attention
towards degradable stents. Additive manufacturing attracts increasingly recognition as manufacturing technique
for medical implants and devices. This work presents 3D printing as promising manufacturing technique for
fabrication of biodegradable and drug-eluting stents. Three well-established configurations of stents were
recreated, and printing protocols established. The anti-proliferative agent paclitaxel was incorporated onto the
host polymer poly(ε-caprolactone) (PCL) to address current stent issues such as in-stent restenosis. Mechanical
properties tests were carried out to investigate the influence of the drug-loading. In vitro release studies were
undertaken to evaluate the drug-elution behaviour of paclitaxel-PCL-stents, presenting a sustained linear release
profile of the drug over 21 days. Together the results demonstrated in this work indicate that additive
manufacturing has a significant place in the future manufacture of stents.

Acknowledgments

Acknowledgments
“It’s a long way to the top, if you wanna Rock’n’Roll”
Ronald Belford ‘Bon’ Scott

At first, I would like to express my gratitude to Prof. Paul Dalton and Prof. Gordon Wallace for the opportunity
to work within the Australian Center of Excellence and the Intelligent Polymer Research Institute at the University
of Wollongong.
I would like to thank Dr. Zhilian Yue and Dr. Sepidar Sayyar for their trust in my abilities and their supervision
during this project, helpful advices and support. Additionally, I would like to mention Ali Jeiranikhameneh and
Rhys Cornock for their assistance and expertise in 3D printing.
Throughout this journey, I met many people – first as colleagues, later as friends – I would like to thank. Special
gratitude goes to Melanie Gillies, Jo Williams, Dan Yang, Luciana Daikuara, Sian Wright, Juliane Kade, Marius
Berthel, Angeline Eder and Nick Hüttner.
I would like to acknowledge my whole family for their interest and trust in my work and choices, as well as their
constant questions of what I am actually doing. Their support and encouragement have led me through my years
of studies. Without them I would not have made it this far.
Finally, my very profound gratitude goes to my beloved girlfriend Sarah Carter. You are the one who keeps
inspiring me to aim higher. Your endless support, encouragement, constructive views, trust and our video calls
gave me confidence, motivation and passion throughout this project – for which I will always be grateful.

Certification

Certification
I, M ax i m N oe l B r o d m e r k e l , declare that this thesis submitted in fulfilment of the requirements for the
conferral of the degree Master of Philosophy, from the University of Wollongong, is wholly my own work unless
otherwise referenced or acknowledged. This document has not been submitted for qualifications at any other
academic institution.

Maxim Noel Brodmerkel
30th August 2019

Statement on the Biofabrication Double Degree

Statement on the Biofabrication Double Degree
This section shall serve to clarify the organization and structure within the Double Degree Masters of
Biofabrication between the Julius-Maximilians-Universität Würzburg (Germany) and the University of
Wollongong (Australia).
The Biofabrication Double Degree Master’s programme was started according to the Memorandum of Agreement
between Queensland University of Technology, University of Wollongong, Julius-Maximilians-Universität
Würzburg and Utrecht University. Students in the programme were expected to obtain a Master’s degree from
one European and one Australian institution.
At first, students enrolled in Würzburg as home institution undertook one semester (6 month) of studies. These
studies comprised four compulsory and two elective courses (total of 30 ECTS), detailed hereinafter:
Biofabrication
Fundamentals of Tissue Engineering and Quality Management
Physical Chemistry of Supramolecular Assemblies
Polymers II
Microsystems for biological and medicinal Applications
Polymer Materials 1: Technology of Polymer Modification
Students enrolled at the overseas participating institution during second and third semester for a 10-month
internship, undertaking a research project documented in this thesis submitted to the University of Wollongong
(60 ECTS).
At last, a Master’s Thesis was written about research carried out at the Julius-Maximilians-Universität Würzburg
during the final semester (30 ECTS), appended to this document and submitted to the University of Würzburg to
fulfil the requirements for the home Master’s Degree in Biofabrication.

List of Abbreviations

List of Abbreviations
3D

3-dimensional

BENESTENT

Belgium Netherlands Stent Trial

BMS

Bare-metal stents

BRS

Bioresorbable stent

CAD

Computer aided design

CFD

Computational fluid dynamics

CVD

Cardiovascular disease

CVS

Cardiovascular stents

DAPT

Dual antiplatelet therapy

DES

Drug-eluting stents

eNOS

Endothelial nitric oxide synthase

EP

Extrusion printing

FDA

Food and Drug Administration

FDM

Fused-deposition modelling

FKBP-12

FK-506 binding protein-12

GHE

Global Health Estimates

IHD

Ischaemic heart disease

ISR

In-stent restenosis

LDL

Low-density cholesterol

List of Abbreviations
LSR

Late stent restenosis

mTOR

Mammalian target of rapamycin

NCD

Non-communicable disease

NO

Nitric oxide

NWSS

Near-wall shear-stress

PBMA

Poly (n-butyl methacrylate)

PCL

Poly(ε-caprolactone)

PES

Paclitaxel-eluting stent

PEVA

Poly (ethylene-co-vinyl acetate)

PLLA

Poly-L-lactic acid

PTA

Percutaneous transluminal angioplasty

PTCA

Percutaneous transluminal coronary angioplasty

PXC

Paclitaxel

R-stent

Rhombus patterned stent

SES

Sirolimus-eluting stent

SF

Stent fracture

SIBS

Poly (styrene-b-isobutylene-b-styrene)

SS

Stainless steel

STL

Standard Tessellation Language

STRESS

Stent Restenosis Study

List of Abbreviations
S-stent

Sinusoidal-like patterned stent

T-stent

Triangle-wave patterned stent

TE

Tissue engineering

US

United States

VSMC

Vascular smooth muscle cells

WHO

World Health Organization

Table of Contents

Table of Contents
List of Tables, Figures and Illustrations ........................................................................................ 1
1.

Introduction ............................................................................................................................. 3
1.1

Literature Review ........................................................................................................... 3

1.1.1

Foreword..................................................................................................................... 3

1.1.2

Cardiovascular diseases ............................................................................................. 3

1.1.2.1

The pathogenesis of atherosclerosis ................................................................ 5

1.1.2.2

Percutaneous transluminal angioplasty intervention ...................................... 7

1.1.3

1.1.3.1

Bare-metal stents .............................................................................................. 8

1.1.3.2

Drug-eluting stents ......................................................................................... 10

1.1.3.3

Bioresorbable stents........................................................................................ 13

1.1.3.4

Stent design ..................................................................................................... 13

1.1.4

Additive manufacturing in Biofabrication.............................................................. 14

1.1.4.1

3D printing of polymeric stents ..................................................................... 15

1.1.4.2

3D printed drug-eluting stents – State of the art ........................................... 16

1.2
2.

Evolution of cardiovascular stents ............................................................................ 8

Project Objectives ........................................................................................................ 17

Materials & Methods ............................................................................................................ 19
2.1
2.1.1

Establishing basic Printing Protocols.......................................................................... 19
Stent Designing ....................................................................................................... 19

Table of Contents
2.1.2

Stent Printing ........................................................................................................... 23

2.1.3

Microscopic characterisation of 3D printed stents................................................ 24

2.1.4

Mechanical characterisation of 3D printed stents ................................................. 25

2.1.4.1

Sample preparation .......................................................................................... 25

2.1.4.2

Mechanical Testing.......................................................................................... 26

2.2

3.

3D printing of polymeric stents with paclitaxel-eluting feature................................ 27

2.2.1

Preparation of PCL-drug composite ...................................................................... 27

2.2.2

Differential Scanning Calorimetry......................................................................... 27

2.2.3

Rheology Measurements ........................................................................................ 27

2.2.4

Raman Spectroscopy............................................................................................... 28

2.2.5

3D printing of drug-incorporated stents ................................................................ 28

2.2.6

Scanning Electron Microscope Imaging................................................................ 28

2.2.7

Mechanical Properties Testing ............................................................................... 29

2.2.8

In Vitro Drug Release ............................................................................................. 29

Results & Discussion ............................................................................................................ 31
3.1

3D printing of biodegradable PCL stents ................................................................... 31

3.2

Mechanical testing of 3D printed PCL stents ............................................................. 33

3.3

Characterisation of PCL-PXC composites for 3D printing ....................................... 36

3.3.1

Thermal properties of the printed materials ........................................................... 37

3.3.2

Rheological properties of the printed materials ..................................................... 38

3.3.3

Raman spectroscopy results .................................................................................... 39

Table of Contents
3.4

SEM imaging of 3D printed stents .............................................................................. 42

3.5

Effects of drug loading on the mechanical properties of 3D printed stents ............. 44

3.6

Drug-elution studies of 3D printed stents ................................................................... 49

4.

Conclusion ............................................................................................................................. 52

5.

Future Recommendations ..................................................................................................... 53

6.

Bibliography .......................................................................................................................... 55

Appendices .................................................................................................................................... 76
Appendix I – T-Stent G-code ................................................................................................... 76
Appendix II – SEM images ...................................................................................................... 78
Appendix III – HPLC calibration............................................................................................. 84
Appendix IV – Elution studies time marks ............................................................................. 86
Appendix V – Dual-material 3D printed stent ........................................................................ 87
Appendix VI – Vessel-simulating flow-through cell .............................................................. 88

List of Tables, Figures and Illustrations

List of Tables, Figures and Illustrations
Figure 1. Death proportions worldwide in 2015.

4

Figure 2. Development of arteriosclerosis.

6

Figure 3. Angiographic image A) before and B) after PTCA.

7

Figure 4. Illustration of the procedure performed at stenting PTCA.

8

Figure 5. Stent manufacturing process and product.

9

Figure 6. Chemical structures of sirolimus, zotarolimus, everolimus and paclitaxel (A)
11
used in DES and their interaction with the cell cycle (B).
Figure 7. Printing process – from image to synthetic, manufactured tissue.

14

Figure 8. AM throughout the years.

15

Table 1. Designed stents.

19

Figure 9. Designed single strut of R-stent (pitch 25) in BioPlotter software.

20

Table 2. List of parameters during R-stent printing.

21

Figure 10. Designed single ring of S-stent in BioPlotter software.

22

Figure 11. Image of KIMM SPS-1000 BioPlotter used in ths work to print PCL-stents.

24

Figure 12. Engineering drawing of designed stent mould parts.

25

Figure 13. Silicon rubber crosslinking to manufacture stent holders.

26

Figure 14. Mechanical compression testing performed.

26

Figure 15. Fabricated stent designs (A) and microscopic images of R-stent intra-strut area
32
(B and C).
Figure 16. Microscopic images of 3D printed stents used for angle determination.

33

Figure 17. Axial compression test results for R-stents.

34

Figure 18. Radial compression test results for R-stents.

34

Table 3. Mechanical properties of the R-stent.

35

Figure 19. Prepared materials through incorporation of PXC into PCL.

36

Figure 20. DSC spectra of PCL, PXC and prepared blends.

37

Figure 21. Rheology data of PCL, PXC and the drug-loaded composites.

38

Figure 22. Raman spectra of PCL, PXC and their composites.

40

3D printed degradable stents with controlled drug delivery capabilities

1

List of Tables, Figures and Illustrations
Table 4. Assignments of characteristic Raman bands.

40

Figure 23. Representative SEM images of top surface of 3D printed drug-free PCL stents.

42

Figure 24. Representative SEM images of the fractured surface of 3D printed stents.

43

Figure 25. Axial compression data of PCL and PCL-PXC stents.

45

Figure 26. Radial compression data of PCL and PCL-PXC stents.

46

Table 5. Mechanical compression properties of PCL and PCL-PXC loaded stents.

47

Figure 27. Tensile test results of PCL and PCL-PXC stents.

48

Table 6. Tensile test results of PCL and PCL-PXC loaded stents.

49

Figure 28. Release profiles of the PCL-PXC 3D printed stents over 21 days.

50

Table 7. Total drug-loading of the 3D printed stents.

51

Figure 29. Original SEM image of a single T-wave ring.

78

Figure 30. Original SEM image of a T-wave ring surface.

79

Figure 31. Original SEM image of break edge of a 3D printed stent.

80

Figure 32. Original SEM surface images of a PCL stent.

81

Figure 33. Original SEM surface images of a PCL-PXC 1 % stent.

82

Figure 34. Original SEM surface images of a PCL-PXC 5 % stent.

83

Table 8. Standards concentration to establish HPLC calibration curve.

84

Figure 35. Calibration curve for HPLC measurements

85

Table 9. Time marks of release medium extraction.

86

Figure 36. Dual-material 3D printed stents.

87

Figure 37. Engineering drawing of designed flow-through main cell.

88

Figure 38. Engineering drawing of cell sealing lid

88

Figure 39. Drawing of inserted disk to separate the hydrogel from glass beads.

89

Figure 40. Drawing of nozzle tip for the in- and outlet of the circulating fluid.

89

3D printed degradable stents with controlled drug delivery capabilities

2

The Project Objective

1.

Introduction

1.1

Literature Review

1.1.1

Foreword

The majority of cardiovascular diseases (CVDs) are classified as ischaemic heart diseases (IHDs). With over 8.73
million deaths in 2015, IHDs account for approximately 50% of all CVDs and present a global health burden [1].
IHD are mainly caused by atherosclerosis, which refers to lumen narrowing of arteries [2]. The golden standard to
treat an advanced state of atherosclerosis in the heart is by performing a percutaneous transluminal coronary
angioplasty (PTCA) [3], during which a balloon-tipped catheter is inserted into the narrowed part of the lumen and
inflated, reopening the vessel, and restoring the blood flow.
Stent implantation during PTCA improves the long-term restoring effect and obviates acute vascular recoil [4].
However, the stenting procedure using bare-metal stents (BMS) may lead to immune system responses, causing
post-operational challenges such as restenosis or thrombosis. Implanting drug-eluting stents (DES) – consisting of
a metal stent base with a polymer-drug-coating – has led to more favourable angiographic outcomes when
compared to BMS, yet still face late response issues due to the non-degradable stent base [5, 6]. These drawbacks
can be overcome through development of degradable, drug-eluting stents [7]. The development of new techniques
such as additive manufacturing (AM) has made it possible to fabricate three-dimensional (3D) structures by having
far better control over their geometry in an automatic and accurate manner. AM techniques, namely fused
deposition modelling (FDM), can be utilised to fabricate polymer-based stents in different configurations [8].
The focus of this work is design, fabrication and characterization of polymer-based drug-eluting stents with
variable configurations using AM technique. In order to do this, printing protocols for stent fabrication have been
developed and optimized. Introduction of drug-delivery and investigating elution patterns might reveal the possible
application of 3D printed stents as future medical device to treat atherosclerosis.

1.1.2

Cardiovascular diseases

Based on the latest Global Health Estimates (GHE) report from the World Health Organization (WHO), noncommunicable diseases (NCDs) are the major cause of death worldwide. From all deaths in 2015, 70.01 % were
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due to NCDs, meaning a total of 39.36 million incidents. Looking further into detail, 44.79 % – 17.63 million – of
those NCDs were caused by CVDs followed by cancer (22.65 %) and respiratory diseases (9.92 %) (figure 1) [1,
9].

Figure 1. Death proportions worldwide in 2015. Pie charts created with data from Global Health Estimates 2015
of the World Health Organization [1].

Various factors might increase the chance of CVDs, mostly attributed to behavioural (e.g. physical inactivity,
smoking and alcohol abuse) and biological (e.g. uypertension, diabetes) risks [10-12].
Ezzati et al. reported a 90 % increase of blood pressure worldwide from 1975 -2015 [13]. Exaggerated salt intake
was found to be associated with hypertension, which manifests in strokes, infarcts and other harmful conditions
[14-17]. The number of women and men with a body-mass index of 25 kg/m² or greater increased in the past years
dramatically, classified as overweight [18-20]. Obesity and diabetes may lead to conditions such as sleep apnoea
or stroke, to name a few [21, 22]. Although moderate alcohol consumption seems to prevent CVDs, abuse enhances
the risk of developing cardiomyopathy or hypertension [23-26]. Smoking is linked inter alia to a significant
reduction of bioactive nitric oxide (NO) due to the formation of peroxynitrites by smoke contained radicals [27,
28]. Peroxynitrites themselves lead to oxidation of low-density lipoproteins (LDL) to oxidized low-density
lipoproteins (oxLDL), which favour the formation of foam-cells, contributing to atherosclerosis development [29].

3D printed degradable stents with controlled drug delivery capabilities

4

The Project Objective
As shown in figure 1, almost half of all CVDs in 2015 were caused by IHDs. The underlying pathology of this
group of disorders is atherosclerosis – an immune-inflammatory disease of the arterial wall, which results in lumen
narrowing and impedes blood flow and circulation [20, 30-32]. In order to successfully prevent and reduce
atherosclerosis, it is highly important to understand significant factors of its formation.

1.1.2.1 The pathogenesis of atherosclerosis
The human cardiovascular system consists of different kinds of vessels, mainly arteries and veins [33], which
transport oxygen-rich and oxygen-poor blood through the system respectively. In the next section the focus is put
on the arterial structure. Please refer to Rhodin et al. for a more detailed description of the venous structure [33].
In general, the arterial structure comprises three layers: tunica intima, media and adventitia. The tunica intima
describes the innermost monolayer of endothelial cells and their basal membrane. The sub-endothelial tunica
media layer consists of a cell-free composition of elastic and collagenous fibres, as well as vascular smooth muscle
cells (VSMC). The outermost tunica adventitia (or tunica externa) ) is primarily composed of loose connective
tissue made up of fibroblasts and associated collagen fibers and the vasa vasorum- a network of small, vessels
that supply the walls of larger arteries and veins [33].
As briefly mentioned before; atherosclerosis describes the process of ongoing lumen narrowing due to
inflammatory reactions in the vessel wall. Initiation of atherosclerosis is often linked to a change of the endothelial
shear stress (ESS) – a friction induced tangential stress of the blood stream [34-36]. Receptors along the endothelial
layer detect changes of the flow pattern, responding and modulating via mechanosensitive gene expression [11,
37, 38]. Harrison et al. reported the anti-inflammatory, atheroprotective properties of NO, regulated by endothelial
nitric oxide synthase (eNOS) [39]. Low ESS decreases eNOS expression, resulting in NO downregulation which
impedes atheroprotection [40, 41]. Instead, LDL synthesis is upregulated, ultimately resulting in sub-endothelial
accumulation of said lipoproteins through ECs-junction widening [42, 43] (figure 2A), as was shown by Himburg
et al. [44]. Accumulated LDL experiences oxidative stress and form oxLDL, which initializes macrophage
internalization [45-47]. NO absence triggers inflammatory response, promoting inter alia VSMC migration (figure
2B) [2, 48, 49]. VSMC migration and fibroblast growth are followed by fibrous capping, forming atherosclerotic
plaque (figure 2C) [50-52]. Upregulated metalloproteinases expression promotes degradation of the extracellular
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matrix of fibrous cap and vascular wall, ultimately resulting in disruption and thrombus formation (figure 2D) [5358].

Figure 2. Development of arteriosclerosis. A) Increase of permeability of the endothelium results in leukocyte
migration and adhesion. B) Fat-loaded streak formation resulting from VSMC-migration and foam-cell formation.
Process driven by growth factors. C) Growing fibrous-coated lesion through additional macrophage accumulation.
Advanced stages may develop necrotic core. D) Ongoing macrophages activation result in thrombus formation
and ultimately in haemorrhaging rupture. Figures modified from Ross et al. [2].

One way to preventing atherosclerosis is to reduce risk factors, such as diabetes mellitus, hypertension, obesity [9,
57]. Over the years, various interventions aiming at restoring the natural blood flow have been explored. Examples
include atherectomy angiogenesis, angioplasty, brachytherapy and bypass crafting [59-61]. Especially
percutaneous transluminal angioplasty (PTA) has shown promise to restore the natural blood-flow and is therefore
introduced here in more detail.
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1.1.2.2 Percutaneous transluminal angioplasty intervention
Dotter et al. performed the first PTA in 1964 on an atherosclerotic human femoral artery [62]. The procedure of
PTA includes inserting a catheter into the artery system, inflating an attached balloon at the narrowed part, causing
reopening and restoring of the blood flow (figure 3) [63]. The principal surgical approach to treat coronary
atherosclerosis was established by Andreas Grüntzig in 1977, who improved and adjusted the procedure to perform
PTCA, also in some literature referred to as percutaneous coronary intervention [64].

Figure 3. Angiographic image A) before and B) after PTCA. Angiographic images show the successful
restoration of the blood flow. Image modified from Keeley et al. [65].

Successful interventions by PTCA were reported, showed restored blood circulation. However, various cases of
restenosis – re-narrowing of the lumen – were reported within the following months post-operation [66-68].
Vascular recoil after angioplasty was shown to lead to immediate occlusion [69]. Gravanis et al. investigated 22
cases that were treated via PTCA, of which 9 patients died within 24 hours post-operation [70]. Endothelium and
plaque rupture caused by balloon dilatation lead to platelet aggregation and thrombus formation [68].
Conglomeration of VSMC and inflammation were found to be associated with restenosis [71, 72], which, in case
of excessive VSMC stimulation, can result in myointimal proliferation and eventually re-narrowing of the
lumen [73].
Together, these studies show that PTCA is still associated with several limitations. To establish a long-term
restoring effect, a stent may be deployed during inflation process [4].

3D printed degradable stents with controlled drug delivery capabilities

7

The Project Objective

1.1.3

Evolution of cardiovascular stents

The American Heart Association reported over 1 million stenting PTCAs in 2006 [74]. Named after the English
dentist Thomas Stent, these tubular scaffolds have been established for long-term restoring of the blood stream
and to prevent acute post-operative vascular recoil [75, 76]. Puel et al. pioneered the treatment of coronary artery
diseases with the first implantation of a bare metal coronary stent in 1986 [77].

1.1.3.1 Bare-metal stents
The first type of bare-metal stent (BMS) approved by the US Food and Drug Administration (FDA) was the
Palmaz-Schatz balloon-expandable stent [78]. It has a similar mode of action as the PTCA. Yet, the ballooncatheter is tipped with an expandable graft – a stent. At the desired location, the stent is deployed simultaneously
with balloon-inflation, acting as a metallic scaffold and proposing a more permanent stabilization. The process of
stent deployment during PTCA is displayed in figure 4.

Figure 4. Illustration of the procedure performed at stenting PTCA. Stent implantation through balloonexpanding assures restoring of blood stream. Image obtained from Torpy et al. [79].

BMS are primarily manufactured via laser cutting process, in which a laser cuts the desired shape of the stent from
a hollow metallic tube. Ultimately, electro-polishing post-sintering enables surface smoothing and removing of
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residues [80]. This technique allows fabrication of various devices with high resolution and precision, ideal for
medical devices (figure 5) [81, 82]. Materials commonly used for the stent platform are 316L stainless steel (SS),
cobalt-chromium, platinum-chromium and nickel-titanium. Some of mentioned materials being less-visible, others
non-detectable during angiography, radiopaque markers including platinum-iridium or tantalum are added postmanufacturing [83-87].

Figure 5. Stent manufacturing process and product. A) Laser induced cutting of hollow metal tube generates
high precision stent. B) Cut metal foil and similar designed stents promote high resolution of manufacturing
process. Image A) obtained from Moore et al. [80], figure B) obtained from Caves et al. [81].

Various clinical trials indicated a better outcome of coronary artery interventions since stent implantation was
introduced, compared to conventional PTCA. In 1994, the Belgium Netherlands Stent Trial (BENESTENT) and
the Stent Restenosis Study (STRESS) – both randomised studies – compared stent implantation with balloon
angioplasty [88, 89]. BENESTENT reported a restenosis decrease from 32 % to 22 %. Increasing in minimal
luminal diameter after stent implantation verifies that decline. STRESS showed restenosis regression from 42 %
to 32 %. In addition, both trials demonstrated as well, that major clinical events such as death, myocardial
infarction, repeated angioplasty, were more likely to occur in conventional PTCA treated patients, compared to
patients with implanted stent.
Yet, angioplasty involving stent implantation causes physical injury during balloon inflation, triggering
inflammatory response and vascular healing [63, 90]. Stent deployment causes endothelial crushing, leading to
arterial injuries along tunica media and adventitia. Stent-based trauma induces growth factors release, resulting in
VSMC activation. Inflammatory responses due to the metallic stent platform activate inflammatory cells. These
factors among others collaborate to neointimal hyperplasia – new intimal cell growth – resulting in stent covering
and ultimately re-occlusion of the treated artery, in-stent restenosis (ISR) [90, 91]. Additionally, stent fracture (SF)
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was first reported in 2002 by Chowdhury et al. [92]. Platform breakage results from various reasons, such as stent
overexpansion, and may lead to harmful conditions like unstable angina or ISR [93-97].

1.1.3.2 Drug-eluting stents
Drug-eluting stents have been developed to address the above challenge of ISR, which combine metal stent
platforms with polymer coating that enables delivery of pharmacologic agents directly to the injured area of the
artery, or serve as a binder for another layer of drug-laden polymer coating [80]. Cypher™ was the first DES that
successfully underwent a clinical trial and was approved in Europe and by the FDA in in 2002 and 2003
respectively [78]. A variety of drug-eluting stents have been developed, in different platforms and/or using
different metal and polymer materials metal [5, 83, 91].
To date, several drugs have been used as active substances to improve stent response [5, 98]. One example is
sirolimus (or rapamycin), an immunosuppressive, used inter alia prophylactic to prevent organ rejection after
transplantation [99]. By binding to intracellular FK-506 binding protein-12 (FKBP-12), sirolimus inhibits the
mammalian target of rapamycin (mTOR) protein and thereby prevents the progression of cell proliferation in the
G1 phase of the cell cycle [99-102]. Everolimus and zotarolimus are rapamycin-analogues and have similar mTOR
inhibiting properties. However, everolimus and zotarolimus show a slower, but preferred release profile compared
to sirolimus, which is due to a higher lipophilia [101, 103]. Another commonly used drug is paclitaxel (PXC). This
drug is derived from the pacific yew tree Taxus brevifolia [104] and commonly used for cancer treatment due to
its anti-proliterative abilities [105]. PXC Inhibits cell proliferation by binding tubulin, a protein needed to build
microtubules and eminently necessary for cell division (figure 6) [106].
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Figure 6. Chemical structures of sirolimus, zotarolimus, everolimus and paclitaxel (A) used in DES and
their interaction with the cell cycle (B). First three are immunosuppressive agents, binding FKBP-12, inhibiting
the cell cycle progression from G1- to S-phase. PXC is a cytostatic, anti-proliferative drug, binding to α- and βtubulin and thereby interrupting cell division [5]. Image adapted from Martin et al. [83].

Drug-carrier properties such as polymer composition and thickness greatly influence drug release [107]. Three
main release patterns exist for DES, the most common one being drug release via diffusion. The other two involve
drug release based on erosion or dissolution of the carrier material, of which the latter is most frequently used
in metallic, non-polymeric stents [108-111].
The introduction of DES was not only a key step for atherosclerosis treatment, but also to tackle re-narrowing
related issues of BMS. Therefore, the first generation of DES should be accentuated: former mentioned sirolimuseluting Cypher™ stent from J&J Company and PXC-eluting Taxus™ stent, produced by Boston Scientific [5, 86].
The Cypher™ stent consists of a 316L SS BX™ Velocity stent platform, coated with three polymers layers:
parylene C as primer, followed by a polymer blending of poly (ethylene-co-vinyl acetate) (PEVA) and poly (nbutyl methacrylate) (PBMA) in a 67:33 ratio and sirolimus. Final layer consists of PEVA and PBMA, without
drug-incorporation [112]. An Express2™ stent delivery platform is used for the Taxus™ stent. Polymer coating
consists of poly (styrene-b-isobutylene-b-styrene) (SIBS or Translute™) which incorporates PXC [113, 114].
Being the first FDA approved DES, several studies compared the clinical application and outcome of BMS to
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sirolimus- and PXC eluting stents (SES/PES) and their ability to decrease ISR [112, 113]. A randomized, doubleblind trial study showed a significant decrease of ISR in patients treated with the Cypher™ stent, compared to a
control group with BMS implantation [115]. Patients of the control group were found to have a 52.3 % higher
restenosis rate then SES-treated patients. These findings are in agreement with similar studies performed [116118]. Hermit et al. reported a restenosis rate drop of 81 % in diabetes patients with Taxus™ stent implantation,
compared to BMS implantation [119]. Kastrati et al. analysed six general randomized trials of both SES and PES
[120]. Although both DES show significant lower rates of restenosis; data comparison of angiographic controlled
restenosis demonstrates a 3.8 % higher rate for PES (13.1 %) to SES (9.3 %) after implantation. Differences in
stent geometry, drug, coating and release mechanism contribute among others to these results [120-122]. Yet,
follow-up trials regarding subsequent stent response show that DES face late stent restenosis (LSR) [123]. The
main pathological cause is delayed arterial healing due to incomplete endothelialisation and continuous deposition
of fibrin [124]. McFadden et al. reported cases of LSR after discontinuation or termination of prescribed antiplatet
therapy [123]. Dual antiplatelet therapy (DAPT) with aspirin and adenosine di-phosphate-receptor inhibitor
appeared as an excellent oral therapy for thrombosis and haemorrhage reduction, normally prescribed for 3-6
months post-angioplasty [125-129]. Nonetheless, prolongation of DAPT leads to an increase of haemorrhaging
incidents [130]. Supervening, incidents of SF occurred in DES as well as in BMS. Fractures can range from minor
damage, a single strut fracture, to major incidents like a complete separation into two parts, as reported by Umeda
et al. [131, 132]. Surveying 256 patients who received SES PTCA, Aoki et al., reported SF of 2.6 % [133]. In
general, SES seemed to be more like to undergo SF compared to other DES [131, 134-136]. Further investigations
of their performance in vivo, regarding among others system response, clinical outcome, drug-release pattern, lead
to development of the next, second generation of DES [137]. This includes everolimus-eluting Xience V® and
zotarolimus-eluting Endeavor® stent [5, 137].
Summarizing, DES compared to BMS show a significant lower risk of ISR yet face late response issues like LSR
and thrombosis. A potential reason for these issues is the non-degradable stent platform of both BMS and DES.
To tackle this and to improve the clinical outcomes, research has shifted to the development of bioresorbable stents
(BRS) in order to improve clinical outcomes for patients.
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1.1.3.3 Bioresorbable stents
The main idea behind the evolution from BMS to bioresorbable stents (BRS) was to establish a degradable stent
platform, capable to degrade after fulfilling its task. This obviates the formation of thrombosis or LSR and thereby
limits or precludes the need for DAPT. The Igaki–Tamai stent is the first in human implanted BRS and consists of
poly-L-lactic acid (PLLA) without any pharmacological agent [138, 139]. It demonstrated no incident of any major
cardiac event after 6 months implantation in 15 patients [140]. A 1-year follow-up by Ormiston et al. to estimate
long-term performance of BRS showed minimal signs of neoinitmal proliferation, therefore low ISR of
everolimus-eluting degradable stents [141]. In addition to PLLA, a wide selection of biodegradable polymers
might be suitable as material for stent backbones [142, 143].
Alongside polymers; erodible metals such as magnesium- or iron-based have been investigated as potential
materials sources [144-148]. BRS can be manufactured like BMS via laser cutting. However, altering of polymer
properties due to thermal and chemical stress can occur. Moulding describes the process of injecting molten
polymer into a mould of desired design, yet may cause restrictions of thermoplastic behaviour of the polymer [112,
113].

1.1.3.4 Stent design
It has been shown that geometrical properties of stents can significantly affect their function [60, 149]. Strut
thickness was reported to be related to ISR [14, 150]. Thinner struts were found to result in less clinical restenosis,
according to Pache et al. [151]. Gundert et al. investigated the geometrical importance of rhombus-patterned stents
(R-stents) using computational fluid dynamics (CFD) to determine the correlation between vessel-wall
hemodynamics and stent design [152]. During CFD analysis, the intrastrut angle was permitted to verify regarding
its effect on the near-wall shear-stress (NWSS). It was found that an angle between 38.5 and 45 degrees provides
the lowest NWSS rates. CFD might as well be useful in terms of in silico testings on new stent designs, serving to
investigate design hypotheses [153]. Stöckel et al. reviewed numerous stent designs, alerting that focus on
stent evolution should be more in terms of positive application, rather than commercial and marketing [154].
Evaluating designs, numerous stents were found to be possess either rhombus-motived, sinusoidal-like and
triangle-wave patterned as most common shape.
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1.1.4

Additive manufacturing in Biofabrication

The concept of AM, also referred to as 3D printing was developed by Charles Hull in 1980 [155]. Since then, its
use as manufacturing technique ranges inter alia from industrial to medical applications [156, 157]. A certain
model is designed via computer aided design (CAD) software and subsequently converted into an Standard
Tessellation Language (STL) file. Used as data transfer, a STL file connects CAD software with a 3D printer
[158].
Biofabrication describes a multi-disciplinary research field, combining areas of engineering, material science, cell
biology and biotechnology in order to ‘manufacture’ bio-inspired 3D organized structures for tissue engineering
(TE) and regenerative medicine (figure 7) [159, 160].

Figure 7. Printing process – from image to synthetic, manufactured tissue. At first, targeted tissue is imaged,
followed by designing and selection of the printed ‘ink”, materials and cells, 3D printing and being applied to the
targeted applications. Image obtained from Murphy et al. [161].

AM include printing techniques such as extrusion-based, stereolithography, selective laser sintering/melting,
inkjet-printing among others (figure 8A) [160-163]. Whilst several printing techniques are capable to be used in
TE [161, 164, 165] in order to manufacture bone or organ scaffolding, concerns are raised due to the necessity of
the printed materials to be biocompatible [166], which is among the most important factors in order to be FDA
approved. From all above mentioned techniques, extrusion printing stands out due to its advantages regarding
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scaffold printing. It provides in general a better and easier controlling of parameters (temperature, pressure) and
customization (size, shape, material) of the printing process than other techniques. Extrusion printing describes
the layer-by-layer deposition of filaments to create 3D structures [162]. A specific version of extrusion printing is
FDM – suitable to print thermoplastic material, such as poly(ε-caprolactone) (PCL). To print 3D polymeric
structures, the polymer is transferred into a barrel enclosed in a temperature-controlled jacket. The polymer is then
melted by increasing the temperature. By controlling x-, y- and z-axis of the print-head and/or print-base
(depending on used printer) during pump or mechanical controlled filament extrusion, a 3D structure is fabricated
(figure 8B).

Figure 8. AM throughout the years. A) Time-line of AM techniques used for tissue engineering. B) Scheme for
a FDM-printer. Image A) obtained from Melchels et al. [160]. Image B) adapted from Hutmacher et al. [167].

3D printing in general present advantages in terms of availability, manufacture rate or economical aspects [6, 156].
It enables the fabrication of 3D structures in a spatially controlled and reproducible manner, and further introduces
the production of highly customized object and structures, perfectly designed for a targeted application and/or to
address a certain need. The ability of scaffold customization using AM allows an individualized treatment of
patients, making 3D printing a suitable and extremely important manufacturing technique [155].

1.1.4.1 3D printing of polymeric stents
To date, 3D printing of polymeric stents is still in its infancy. Among the abundant literature on polymeric stents
in general, to our knowledge, only a few studies focus on 3D printed polymeric stents. In a study presented by
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Cabrera et al., self-expandable stents created with CAD and FDM were compared to a Nitinol stent for heart valve
implantation in terms of mechanical properties [168]. 3D printing of a dual-coated sirolimus eluting stent with
PCL-platform produced valuable results [8]. Misra et al. printed dual-drug eluting coronary stents consisting of
unfilled and graphene-filled PCL [169]. Graphene as polymer filler was shown to improve their mechanical
properties and biomedical characteristics [170, 171]. Mechanical properties of both stents differ significantly under
applied strain and stress. Moore et al. reported of anecdotal supply chain duration – from manufacturing until stent
deployment – of about 150 days [80]. Further, they postulate a significant decrease to around 20 minutes for stent
manufacturing. Using generating eluting stent in situ software, Moore et al. designed and printed a patient specific
stent, capable to transform imaging data into and remodel a custom stent design in real time.
Although literature regarding research of 3D printing for stent manufacturing is barely available, results suggest
evaluation of 3D printing as possible manufacturing technique. Therefore, FDM as manufacturing process could
be investigated as promising possibility of stent fabrication.

1.1.4.2 3D printed drug-eluting stents – State of the art
As previously discussed, a stent must exhibit a number of important properties in order to fulfil its task: maintaining
its shape over the period of service, the ability to provide the stented area with a pharmacological agent and to
completely biodegrade afterwards – just to mention a few. Especially the capability to deliver a certain drug is
highly important.
Decades of research have shown that cardiovascular stents (CVS) which feature such a drug-delivery capability
are less likely to face incidents like ISR and thrombosis over the period of drug-elution [80, 119, 172, 173]. The
interdisciplinary research field of drug-delivery is gaining attention of researchers, doctors and industry equally
on account of being able to improve and revolutionize the performance of classic medical approaches [174, 175].
Further, it is capable to develop new strategies and therapeutics for various diseases, such as cancer or epilepsy
treatment [176-179]. Whilst past decades of drug-delivery research emphasized the importance of i.e. drug-loaded
nanocarriers as delivery method, various other formulations, inter alia polymer combinations and properties, are
important conditions to face in order to tailor desired release profiles – not only for DES [180-182]. Release from
DES is generally driven by the diffusion of a matrix system, or through the dissolution or degradation of a polymer
membrane, which encapsulates the drug reservoir, or serves as a drug-containing polymer matrix itself [183]. The
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mechanism for controlled delivery can diverge depending on released drug and used biomaterial-carriers, hence
further affect the clinical efficiency [184-186].
Whilst various drugs have been evaluated to be applied in DES, one of the most studied drugs so far is PXC [183,
187]. Given its antiproliferative characteristics, PXC was used amongst first stent-based applications [188].
Various drugs have been explored and introduced into CVS as a thin layer of polymer coating. The drug release
profile mainly depends on the degradation of that polymer-coatings that function as drug-carriers, rather than
degradation or diffusion from a polymeric stent-base [189-193]. Up to date, research into development and
evaluation of drug-eluting polymer-based CVS is limited. One example is given by Rong et al., who investigated
PCL as carrier vehicle in stent applications to provide the affected area with a combination of PXC and 5fluorouracil [194]. However, these stents are manufactured by hot-pressing of PCL-films, hence differ vastly from
conventional manufacturing of CVS.
The last few years saw an increasing trend of exploring novel fabrication techniques for stent manufacturing [195197]. However, whilst most of these studies have demonstrate the advantages of AM such as the freedom of design
and dimensions, only a few include and address essential characteristics the printed stents must comprise, in
particular the drug-delivery feature [80, 198, 199]. Hence, AM of DES exposes a novel research field to explore,
with the potential to establish 3D printing as future state-of-the-art manufacturing method for CVS.

1.2

Project Objectives

Recent research has shown that stents are useful devices for atherosclerosis treatment, yet still face issues that limit
their efficiency. One major hurdle is the foreign body immune response, which is triggered by the non-degradable
stent platform. Whereas introduction of DES improves the acceptance of stent implants until plenary drug-elution,
long-term follow-ups revealed incidents such as LSR. The first attempts of using AM as a fabrication tool for stent
production demonstrated promising results in terms of addressing the challenges of degradation and drug-elution.
The focus of this work is designing, fabricating and characterizing of polymer-based, degradable stents using AM
techniques and PCL. Especially the design-phase, which shows that stents in varying shapes can be printed, is a
key part of this project. To date, several stent types are commercially available; the simplest of which utilises a
repeating rhombus, sinusoidal-like and triangle-wave pattern [154]. These stent patterns are designed and
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fabricated. Part of evaluating AM as application for stent fabrication is to estimate the response of printed stents
to mechanical stress of any kind and assess their mechanical properties. From there, to focus should shift towards
the introduction of drug-delivery abilities. Literature reports a decrease of ISR incidents after deployment of DES,
compared to bare-metal stents, during angioplasty [80, 119, 172, 173]. Providing the supported artery with
pharmacological agents plays a significant role for this outcome. Consequently, major part and next step of this
project was the introduction of a drug-eluting feature to 3D printed stents. With PCL as well-evaluated polymer in
3D printing and PXC as explored agent used in DES, polymer-drug composites in different loading parameters
should be created and all stents printed in same configurations and design. Integrating materials into a polymer
matrix might change specific characteristics and properties and thus is necessary to investigate. Therefore, first
basic experiments should characterise these composites and additionally validate the drug-incorporation.
Furthermore, mechanical testings might reveal an influence of the drug-loading on the material properties.
Fabricated stents from PXC-loaded PCL undergo in vitro release studies. Hence elution rates and profiles can be
determined.
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2.

Materials & Methods

2.1

Establishing basic Printing Protocols

2.1.1

Stent Designing

Three stent types were designed and fabricated for testing, described in table 1.
Table 1. Designed stents.
Abbreviation

Stent design

R-stent

Repeating rhombus pattern

S-stent

Series of rings with a sinusoidal-like pattern, whereby individual rings are linked
with perpendicular connecting paths

T-stent

Series of rings with a triangle-wave pattern, whereby individual rings are linked
with perpendicular connecting paths

R-stents were designed using BioPlotter (V1.2-20110701) software. This program generates the G-code for a
single stent helix (figure 9). By adjusting the pitch – the circular path interval – various R-stents were fabricated
and compared. For an optimal comparison of those, all parameters besides the pitch remained constant (table 2).
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Figure 9. Designed single strut of R-stent (pitch 25) in BioPlotter software.
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Table 2. List of parameters during R-stent printing.
Tol
Circular type

0.1

Base path

Circular

Helix

Axial grid

Isoparam

Object length (mm)

40

Grid shift (%)

0

Layer thickness (mm)

0.4

Grid (mm)

1

Thick shift

100

Grid angle

90

Corner acc (%)

100

A-axis override (%)

100

In order to print a complete stent, the G-code output from the software needed to be modified. This involved
providing additional procedures in the G-code, each commencing with an offset of the rotary stage (A-axis), which
resulted in a series of helices being produced. All R-stents consisted of 6 helices divided into two groups of 3,
whereby individual helices of a set were offset at an angle of 120° to each other. The first set of 3 helices utilised
rotation of the A-axis in the positive direction, while the second set of 3 helices was produced while rotating the
A-axis in the negative direction.
For S-stents, a sinusoidal-like ring was first designed in the BioPlotter software (figure 10) The G-code output
was then manually edited to include multiple sinusoidal rings, each having an X-axis offset relative to the first ring
designed. A series of connectors were then included manually at the conclusion of the code to bind the individual
rings together, forming a complete stent construct.
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Figure 10. Designed single ring of S-stent in BioPlotter software.
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Due to the limitations of the Bioplotter software, this platform was not utilised for the design and fabrication of
the T-stent constructs. A custom G-code script was instead written to facilitate the generation of machine paths for
these designs based on a range of user-input variables (appendix I). The variables which needed to be
accommodated in this script included, but were not limited to, the construct length, number of repeating units in a
ring, number of rings and width of rings.
Briefly, the key steps to the design of an appropriate G-code script were as follows:
1.

Input of necessary G-code preamble functions and concluding code.

2.

Assignment of all variables.

3.

Design, assignment and commenting of subroutine loops for the repeating units, rings and perpendicular
connectors.

4.

2.1.2

Assembly of subroutine loops to generate a tool path for the full construct.

Stent Printing

All in 2.1 presented stents were fabricated on a KIMM SPS-1000 BioPlotter (Mechatronics 4 Technology) using
an extrusion nozzle with a diameter of 400 µm. PCL with an average molecular weight distribution of Mn 45.000
(Sigma-Aldrich) was printed at 125 °C, 250 kPa, and at an adjusted feed rate of 210 mm/min onto a 4 mm diameter
tubular printing base, as depicted in figure 11. Preliminary experiments revealed that a lower molecular weight
would result in brittle structures with low mechanical properties, whilst a higher molecular weight PCL was found
to be almost impossible to print using the 3D printer in this study. Furthermore, this polymer has been chosen for
its availability, its usage in biomedical applications and as it showed promising printing performance on the used
3D printer in previous studies, thus excluding the usage of medical grade PCL [170, 228]. G-codes were loaded in
Mech3 CNC Controller software.
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Figure 11. Image of KIMM SPS-1000 BioPlotter used in this work to print PCL-stents. Technical drawing
highlights important parts of printer head and base.

2.1.3

Microscopic characterisation of 3D printed stents

To assess consistency of printing and strut diameter the fabricated stents were imaged using a stereo microscope
(LEICA M205A). Rhombus-motive intra-strut angles of R-stents were quantified by using the angle tool in ImageJ
software.
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2.1.4

Mechanical characterisation of 3D printed stents

2.1.4.1

Sample preparation

All testings were accomplished at a Shimadzu EZ mechanical tester. In order to assess the mechanical properties,
the 3D printed stents had to be clamped in the mechanical tester. To prevent fracture by the clamps, both ends of
the stents were covered with silicone rubber (Silopren, supplied by Romar Engineering, Australia).
A mould – 8 mm wide, 6 mm depth and 10 mm high – was designed with Solidworks 2017 software, consisting
of a base mould and two detachable wings. The mould was printed from VeroWhite material using Objet
Connex350 3D printer (figure 12).

Figure 12. Engineering drawing of designed stent mould parts.

The stents were mounted into the mould containing silicone rubber. The silicone rubber was then exposed to UVlight (300-450 nm; BlueWave50 light curing spot lamp by Dymax Corporation) for 60 seconds to get crosslinked
(figure 13).
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Figure 13. Silicon rubber crosslinking to manufacture stent holders. A) Printed mould parts and stent. B) Stent
inserting into filled mould before first (left) and second (right) crosslinking. C) Stents with adjusted holders. D)
Crosslinking process using BlueWave50 light curing spot lamp.

2.1.4.2

Mechanical Testing

To assess the mechanical properties, axial and radial compression test were performed for R-stents (n = 3).
Methods were designed as 20-cyclic recovery test with 500 N load cell in Trapezium software. Samples were
tested with a speed of 10 mm/min till maximum compression of 4 mm for axial compression (2 mm for radial).
Obtained data was smoothed by factor 50 in OriginPro 2015 software. Test procedure is displayed in figure 14.

Figure 14. Mechanical compression testing performed. Procedure of axial (A) and radial (B) compression.
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Although it has been shown through mechanical properties tests that these stents have the potential to be used
during angioplasty, addressing the capability of being balloon-inflated of 3D printed stents and evaluating the
balloon rated burst pressure was beyond the scope of this thesis, and thus has not been carried out.

2.2

3D printing of polymeric stents with paclitaxel-eluting feature

2.2.1

Preparation of PCL-drug composite

PCL-paclitaxel with 1% or 5% (wt.%) drug loading was prepared. The yield is 95.4 % for 1% loading, and 94.5%
for 5% loading. Briefly, 5.02 g PCL (Mn 45.000, Sigma-Aldrich, Germany) and PXC (Scientifix, Australia, 50.9
mg for 1% loading, 250.2 mg for 5% loading) were dissolved in 25 mL chloroform (CHCl3) under stirring
overnight. The PCL- paclitaxel composite was isolated by precipitation of the solution into cooled n-hexane
(C6H14), collected by removing surplus solvents, and vacuum-dried at room temperature for 12 h.

2.2.2

Differential Scanning Calorimetry

Differential scanning calorimetry (DSC) was used to evaluate the thermal behaviour of the prepared PCL-PXC
composites. Thermograms were obtained of approximately 6 ± 0.50 mg PCL, PXC and PCL-PXC composites
using a TA Instruments Q100 DSC. Samples were heated in an aluminium pan from 25 to 130 °C at a heating rate
of 10 °C/min under nitrogen atmosphere. Gained data was analysed using TA QSeries DSC software.

2.2.3

Rheology Measurements

To investigate the effect of the drug-incorporation on the viscosity of PCL, and therefore its printability,
rheological properties of PCL and the PCL-PXC composites were tested on a TA Instruments AR-G2 rheometer.
Measurements were performed with a gap of 500-µm using 12-mm diameter parallel plates. Viscosity tests were
performed at steady state flow and ramped temperature; first with varying shear rate from 0.01 to 1000 1/s at
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120 °C, second at constant shear rate (1 1/s) and increasing temperature from 70 to 160 °C at a ramping rate of
5 °C/min. Obtained data was examined using the manufacturer provided software TA Rheology Advantage.

2.2.4

Raman Spectroscopy

Raman spectra were recorded using LabRam HR 800 Raman Spectrometer (Jobin Yvon, Horiba, Japan), with a
632.81 nm (13.50 mV) Helium-Neon-laser, grating of 300 and an exposure time of 10 s to confirm a successful
drug-incorporation of PXC in PCL.

2.2.5

3D printing of drug-incorporated stents

Stents presented in 3.2 were printed following the same protocol as reported in Chapter 3.1.2 Stent Printing, on a
KIMM SPS-1000 BioPlotter (Mechatronics 4 Technology) at 120 °C and 250 kPa N2-pressure. PCL (Mn 45.000,
Sigma-Aldrich, Germany) and previously mentioned PCL-PXC composites were used as materials, extruded
through a 400 µm nozzle on a 4 mm diameter tubular printing base.
Three different stent designs were established during this project, favouring rhomboidal, sinusoidal and trianglewaved (T-wave) patterns. The T-wave design features configurations editing via G-code programming, making it
the easiest to access, edit and print. Hence, the T-wave model was chosen as stent design. T-stents with 4 mm
diameter were printed with various lengths, 32 mm length for mechanical testing, 10 mm (PCL-PXC 1 % loading)
and 5 mm length (PCL-PXC 5 % loading) for drug release study.

2.2.6

Scanning Electron Microscope Imaging

Scanning electron microscope (SEM) images were obtained to study the morphology of 3D printed stents. Fracture
surfaces for SEM were prepared by freezing the stent material in liquid nitrogen and then fracturing it with a cold
metal block. Suitable fragments of the stent were then mounted on an aluminium support stub on conductive carbon
tape (SPI products) and sputter coated with 10 nm platinum using a Dynavac SC100MS magnetron sputter coater
(Dynavac, Australia). SEM imaging was carried out in a JSM7500FA cold Field Emission Gun Scanning Electron
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Microscope (JEOL Tokyo, Japan) at an accelerating voltage of 5kV and a probe current setting of 7. Images were
obtained in magnification of 30, 600 and 3500 and edited to improve the visibility of the scale bars (original images
in appendix II).

2.2.7

Mechanical Properties Testing

Mechanical properties of the samples were measured using a Shimadzu EZ mechanical tester (Shimadzu Corp.,
Japan) to investigate the influence of drug-incorporation on PCL. Thus, axial and radial compression properties as
well as tensile measurements were carried out (n = 3). For axial compression and tensile tests, both ends of stent
samples were covered with cross-linked silicone rubber (Silopren, supplied by Romar Engineering, Australia) to
avoid fracturing of the stent during the measurement. The silicone cover was crosslinked using a BlueWave50
UV-light (300-450 nm; Dymax Corporation, USA).
Compression tests were carried out using a 500 N load cell and compression speed of 10 mm/min in 20-cyclic
recovery test (maximum compression: 4 mm axial, 2 mm radial). Additionally, samples have been evaluated to
estimate their response to tensile stress. Therefore, stents have been tested with a 500 N load cell at a tensile speed
of 10 mm/minute. All methods were created with Trapezium software. Compression data obtained was smoothed
in OriginPro 2018 software by factor 50.

2.2.8

In Vitro Drug Release

Release kinetics of 3D printed stents of 10 mm and 5 mm length with 1 % and 5 % loading respectively were
conducted in phosphate buffer saline (PBS) (pH 7.4) with 0.05 % (w/w) of surfactant Tween-20. To improve the
solubility of PXC and to keep sink conditions, 0.05 % (w/w) of surfactant Tween-20 (Sigma-Aldrich, Germany)
was added to PBS. Sample vials containing 1 mL (1 % loaded stents) or 3 mL (5 % loading) were placed in shaking
bath at 37 °C. The release medium was withdrawn completely and replaced by fresh PBS solution at predefined
time marks every 24 h. Total drug-loading was estimated by ethanol extraction and determined by HPLC.
Drug release samples were prepared by filtering 300 µL of each sample through 0.22 µm pore sized hydrophilic
polytetrafluoroethylene syringe filters (MicroScience Hydraflow) into 300 µL polypropylene HPLC vials (J.G.
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Finneran Associates, USA). Please refer to appendix III for the protocol used to prepare the HPLC standards for
calibration.
The amounts of drug being released were evaluated with HPLC on LC1260 Infinity (Agilent Technologies, USA)
with a ZORBAX Eclipse Plus C18 column (Agilent Technologies, USA). UV detection was performed at 230 nm
at constant column temperature of 35 °C, monitored by ChemStation for LC systems software. The mobile phase
was composed of milliQ water (milli Q H2O) and acetonitrile (CH3CN) (ChemStore, Australia) in a ratio of 55 %
to 45 %. Flow rate was set at 1.2 mL/min with a sample injection volume of 10 µL. PXC was detected at a retention
time of 8 minutes.
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3.

Results & Discussion

3.1

3D printing of biodegradable PCL stents

The main objective of this project was to investigate feasibility of 3D printing PCL-based stents with different
patterns using a KIMM SPS-1000 BioPlotter. Geometrical properties of stents were shown to be able to influence
their later performance [60, 149], thus fitting patterns were chosen in correspondence with literature and already
applied stent systems. Hence, three models were designed by using BioPlotter software and G-code programming:
rhombus, triangle-wave and sinusoidal-like. As depicted in figure 15A, all pre-defined geometries were
successfully printed.
Primary focus was on R-stents as it was the simplest construct printed. Microscopic images of the intra-strut areas
revealed a uniform printed first layer. However, overlap-points with second layer were found to result in strut
widening (figure 15 B and C).
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Figure 15. Fabricated stent designs (A) and microscopic images of R-stent intra-strut area (B and C).
Enlarged images of a rhombus pattern (B) and strut connection (C) show uniformly printed underlying layer.
Overlapping sections of second layer with previous leads to strut widening.

CFD of R-stents revealed that intra-strut angles between 38.5 and 45 degrees caused minimal dynamic flow
disturbance and therefore the lowest NWSS [152]. During the printing process, the first polymer layer was printed
along the clockwise rotating printing base. In order to complete the print of a R-stent, the rotation direction of the
print base was changed to counter-clockwise. As such, the second polymer layer overlays at specific locations,
which were denoted overlap points. A depiction of such an overlap-point is shown in figure 15C. Here, a clear
disadvantage of an overlap-point can be observed, as it effectively results in strut-widening when the second, outer
layer is printed over the inner polymer struts, which could potentially result in a loss of mechanical strength.
Whilst strut widening at overlap points has been observed for R-stents, focus of this project was to achieve printing
R-stents with an instar-strut angle according to Gundert et al. Therefore, overlap-points widening was not further
investigated, yet should be made subject of future work. Fabricating stents with optimum intra-strut angles
(between 38.5 and 45 degrees) was achieved by adjusting the pitch in BioPlotter software. It was found that by
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varying the pitch from 25 to 28 intra-strut angles of 44.06 °, 42.09 °, 40.59 ° and 39.87 ° can be achieved
respectively. Microscopic images of printed R-stents are shown in figure 16.

Figure 16. Microscopic images of 3D printed stents used for angle determination. Images A-D) Show intrastrut areas of stents found to range in between 38.5 and 45 degrees (as postulated by Gundert et al [152].), ranging
in pitch from 25 (A) to 28 (D). Determined angles are displayed respectively.

3.2

Mechanical testing of 3D printed PCL stents

The mechanical properties of the stents, differing in pitch from 25 to 28, were measured by axial and radial
compression. The results are shown in figure 15 (axial compression) and figure 16 (radial compression) for stents
with angles of 44.06 °, 42.09 °, 40.59 ° and 39.87 ° (A to D respectively in figure 17 and 18).
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Figure 17. Axial compression test results for R-stents. Graphs relate to intra-strut angles of 44.06 ° (A), 42.09 °
(B), 40.59 ° (C) and 39.87 ° (D).

Figure 18. Radial compression test results for R-stents. Graphs relate to intra-strut angles of 44.06 ° (A), 42.09 °
(B), 40.59 ° (C) and 39.87 ° (D).
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In all samples, a large hysteresis is observable in the first cycle when they are subjected to axial cyclic compression,
a common observation of viscoelastic materials [200]. The hysteresis then decreased by increasing the number of
cycles as most of the hysteresis occurs in the first cycle. Figure 17B shows smaller hysteresis and force softening
compared to other three samples along with insignificant change in load/unload paths. On the other hand, samples
of 42.09 ° and 40.59 ° intra-strut angles in figure 17 required a higher force (~0.9 N) for 4 mm displacement, with
sample 15C demonstrating smaller force softening. For samples 17C and 17D, a consistency of the load and unload
path is observable, determining less occurring deformation than 17A and 17B. Radial compression results show a
smaller hysteresis compared with axial results, meaning less deformation is occurring during radial compression.
Furthermore, sample 18B requires a force of ~1.3 (± 0.11) N to deform and shows a nearly aligning load/unload
paths and therefore small force softening. Figure 18C shows an insignificant change in load/unload paths, with
roughly 1.0 (± 0.06) N for 2 mm displacement. Samples 18A and 18D display no uniform overlap, suggesting that
with each additional cycle more deformation and force softening occurs. Yet, sample 18D needs less force to
deform than 16A. An overview of mechanical properties of R-stents is given in table 3.
Table 3. Mechanical properties of the R-stent. Overview of the results for R-stents comprising different intrastrut angles.
Mechanical test

Axial compression

Radial compression

Degree

Maximum force

Strain

[°]

[N]

[cm]

44.06

0.45 (± 0.12)

4

42.09

0.32 (± 0.17)

4

40.59

0.94 (± 0.23)

4

39.87

0.78 (± 0.07)

4

44.06

0.98 (± 0.16)

2

42.09

1.3 (± 0.11)

2

40.59

1.0 (± 0.06)

2

39.87

0.80 (± 0.12)

2

Based on these results, showing smaller hysteresis and force softening, and further highest required force of
~1.3 N, it can be concluded that stents with an intra-strut angle of 42.09 ° possess better mechanical properties
compared to other angles. Less force softening, as shown in figure 17B as well as 18B, due to a small hysteresis
and overlapping load/unload paths, could emphasize a materials ability to withstand reoccurring applied stress.
Especially for stents and their final application this is very important, as implanted the structure will face stress
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such as blood flow or compression by the lumen [154, 233]. Preliminary tests showed that 3D printing is a
promising manufacturing technique for stent fabrication. Being able to create and customize a CAD supported
scheme is a great advantage compared to conventional manufacturing techniques.

3.3

Characterisation of PCL-PXC composites for 3D printing

PXC as a pharmacological agent was incorporated into PCL as carrier-polymer in different loadings. In reference
with the published data in literature, drug loading was selected as 1 and 5 % of PXC, respectively [114]. By
dissolving both educts in chloroform, a uniform incorporation of PXC in PCL on molecular level and as a result a
continuous drug-elution was tried to be achieved. Both prepared composites in comparison to pure PCL are
presented in figure 19. Consequently, next experiments should confirm if the intended incorporation was achieved.

Figure 19. Prepared materials through incorporation of PXC into PCL. From left to right: pristine PCL, 1 %
PCL-PXC and 5 % PCL-PXC.
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3.3.1 Thermal properties of the printed materials
DSC is a powerful tool in order to investigate how materials respond to heat and thus gives insight into their
thermal properties[201, 202]. In this study, DSC was used to estimate the effect of drug-incorporation on thermal
behaviour of PCL (figure 20).

Figure 20. DSC spectra of PCL, PXC and prepared blends. Thermograms show minimal influence of
incorporation of PXC on the thermal behaviour of PCL.

Given the DSC results, no major influence of PXC-incorporation can be observed from the thermograms. Melting
point of PCL was measured at 65.7 ˚C, which changed insignificantly for 1 % PXC-loading to 67.5 ˚C and 5 %
loading to 64.4 ˚C, given that the instrument error lies within 1 to 2 ˚C. Literature reports a melting point of PCL
within 59 to 6 ˚C [203-205]. Same trend can be observed for the recrystallization all samples – PCL crystallized
at 26.4 ˚C, for 1 % PXC-loading at 27.3 ˚C and 5 % loading at 24.1 ˚C. DSC graphs show that the incorporation
of PXC does not affect the crystallization of PCL significantly, which correlates with published data [203-205].
Furthermore, the decomposition temperature for PXC amidst 213 to 216 ˚C assures no significant degradation of
the drug during 3D printing, which was carried out at 120 ˚C. This is in line with the trend observed for the PXC
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in the DSC measurements, and consistent with the previous study by Liggins et al. [206]. In summary, the DSC
characterisation shows a negligible impact on drug-loading onto PCL.

3.3.2 Rheological properties of the printed materials
Evaluation of the rheological properties of materials is an important step in ink characterization in order to obtain
vital understanding of polymer behaviors during printing [207-209]. The rheological behavior of all materials were
examined in two experiments, temperature sweep to study the effect of temperature on the viscosity of the samples,
and shear rate sweep to study the effect of shear rate on the viscosity of the materials at the printing temperature
(figure 21).

Figure 21. Rheology data of PCL, PXC and the drug-loaded composites. (A) Ramped temperature from 70 to
160 ˚C at constant shear rate of 1 rad/s. (B) Ramped shear rate at fixed 120 ˚C. As can be observed in both diagrams,
the incorporation of PXC leads to a minimal drop of the viscosity at the set printing temperature for higher shear
rates above 1 rad/s.

The viscosity values for the temperature sweep from 70 to 160 ˚C are shown in figure 21A. At lower temperature
(70 to 77 °C), the viscosity of the drug-loaded polymers is higher compared to PCL. An explanation could be an
intermolecular interaction of the drug-particles with the host polymer chains. The incorporation might add PXCmolecules in between PCL polymer chains, hence resulting in a confinement of their movement, which manifests
in higher viscosity. Similar observations are reported in literature for rheology of polymer-filler blends, in which
fillers such as silica or graphite oxide are able to alter the properties of a host polymer [210-212]. Polymer chain
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movement increases as the temperature rises, hence leading to a decrease in viscosity, explaining the trend
displayed in figure 21A. At the printing temperature of 120 ˚C, the viscosity of the polymer host PCL dropped so
low that the influence of the PXC-particles on the polymer chains can be considered insignificant. Thus, a similar
trend for all tested materials can be observed.
Data of the shear rate sweep is presented in figure 21B and shows similar results at lower shear rate as in figure
21A for lower temperature, higher viscosity of the PCL-PXC blends as resultant of the drug-particle incorporation
[211, 212]. The trend obtained for PCL is similar as reported in literature, with a sudden drop at around 20 rad/s
[213], as the polymeric network and the bonds within break as a result of the applied shear stress.. Opposed to the
PCL-data, viscosity of the composites drops in two steps, first between 0.01 to 5 1/s, and later at 20 1/s. Similar
trends were reported in literature for rheological studies on polymer-filler blends [210, 214-217]. The first drop
indicates the shear stress required to disrupt the polymer-particle network, thus breaking the bonds between the
PCL-chains and PXC-particles [210, 215, 217]. The second drop occurs at same shear rate as the pristine PCLsample, stating a collapse of the bonds between the PCL-network [210, 217, 218]. At higher shear rates, the
viscosity of all tested materials decreases further. This reduction of viscosity occurs on account of shear thinning,
describing the disruption of weak, physical bonds within the polymer network by shear [210, 218]. Putting the
results for both rheological measurements together, accomplished experiments confirm a viscosity drop of PCL at
higher shear rate after drug-loading and therefore support and validate our observations.

3.3.3 Raman spectroscopy results
Raman spectroscopy was employed to examine the effect of drug loading on the properties of PCL-PXC
composites. Raman spectroscopy is a sensitive method to analyse materials by detecting molecular vibrations via
laser beam stimulation, for which can be used to characterize pharmacological agents in polymer carriers [219222]. Functional groups in the molecule structure of a compound respond differently to laser stimulation during
Raman spectroscopy, resulting in peaks in different positions and intensities displayed in a unique spectrum.
Consequently, these spectra can be utilised as fingerprints to identify the structural compositions. Raman
spectroscopy was used to investigate the possible interaction between PCL and PXC. In theory, a successful
incorporation should be recognizable by the observation of basic PCL- and PXC-specific peaks, of which latter
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shows increased intensities for the higher drug-loaded material. The prominent peaks of materials are analysed
and compared with data obtained from literature [194, 223-228]. Results are presented in figure 22 and table 4.

Figure 22. Raman spectra of PCL, PXC and their composites. Y-axis offset shows a successful incorporation
of PXC as demonstrated by prominent peaks at 1000 and 1600 cm-1, characteristic for PXC [223, 224, 227].

Table 4. Assignments of characteristic Raman bands. Literature used for comparison, please refer to [194, 223228].
Material

PCL

Raman peaks
−1

Literature

Assignment

[cm ]

[cm−1]

1109

1106-1107

Skeletal vibrations

1282-1303

1281-1303

ω(CH2)

1724

1721-1726

ν(C=O)
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PXC

PCL-PXC 1 %

PCL-PXC 5 %

1003

1003

γ(C-H) in plane

1605

1581-1608

ν(C–C)

1716

1714-1727

ν(C=O)

999

1003

γ(C-H) in plane

1284-1303

1281-1303

ω(CH2)

1107

1106-1107

Skeletal vibrations

1601

1581-1608

ν(C–C)

1724

1721-1726

ν(C=O)

1000

1003

γ(C-H) in plane

1107

1106-1107

Skeletal vibrations

1282-1303

1281-1303

ω(CH2)

1601

1581-1608

ν(C–C)

1724

1721-1726

ν(C=O)

The polymeric backbone of PCL occurs at 1109 cm-1 due to skeletal vibrations and in a region of 1282 to 1303
cm-1 for the methylene groups. Same trends appear for the composites at 1107 cm-1 for the skeletal vibrations, as
well as amid 1284 to 1303 cm-1 for the 1 % loaded PCL and 1282 to 1303 cm-1 for 5 % incorporation. Two
prominent peaks can be observed for PXC at 1003 and 1605 cm-1, ascribed to deformation stretching of C-H and
C-C respectively [215, 219]. Both prepared composites feature the same peaks, yet in reduced intensities, which
can be traced back to the low amount of PXC incorporated in those composites. As a result, the peak for PCLPXC 5 % possesses a higher intensity than PCL-PXC 1 %. Lastly, a characteristic peak in the Raman spectrum of
PCL is shown at 1724 cm-1, which is defined as a typical carbonyl group absorption band caused by C=O
stretching. PXC expresses the same vibration at 1716 cm-1, both drug-loaded composites as well at 1724 cm-1 [215220]. All above described peaks match with data obtained from literature [215-220]. Particularly the increasing
peaks for the 1 to 5 % loaded PCL verify not only a successful incorporation per se, but as well give hint of the
intended concentration. Similar trends were observed for different parts of the samples, indicating a homogenous
dispersion of PXC into the polymer matrix without any significant effect on the chemical structure of the host
polymer.
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3.4

SEM imaging of 3D printed stents

Drug-eluting PCL stents were printed in T-wave pattern, and their surface morphologies were examined using
SEM (figure 23).

A)

B)

C)

Figure 23. Representative SEM images of top surface of 3D printed drug-free PCL stents. (A) Single T-wave
ring shows smooth and consistent print. (B) Magnified insight reveals perforated surface, potential able to support
drug-elution. (C) Left side: stent surface; right side: fracture surface.

Figure 23A reveals a smooth print of a single stent ring at a lower magnification. When observed under a higher
magnification, figure 23B and C, the stent showed a network of small gaps across the stent and fracture surface, a
common observation for PCL after the polymer melt hardened [229]. Pinholes and grains are commonly observed
during the 3D printing process of PCL, and SEM pictures showing these are published in literature [229, 267-269].
Pinholes and grains, latter often due to dust contamination, are linked to the applied printing parameters. As such,
careful optimization of the printing protocols and process might be able to minimise these defects, yet was not in
the scope of the presented study. On the other hand, these visible pinholes could promote the elution of PXC.
Whilst other incorporations methods reveal for example the typical spherical shape of drug-nanoparticles [230232], this project aimed to incorporate PXC on a molecular level, meaning to achieve an uniform distribution of
the drug throughout PCL. To assess this, SEM images of the fracture surfaces of both PCL-PXC composites in
comparison with pure PCL as control were taken at a magnification of 600 and 3500. Obtained images are
displayed in figure 24.
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Figure 24. SEM images of the fractured surface of 3D printed stents. Left column: 600 magnification; right
column: 3500 magnification. All obtained SEM images show absence of crystalline PXC-clusters, indicating
uniform incorporation on molecular level.
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Overall, no clear differences were observed between all 3D printed materials. Furthermore, the structure and
morphology indicate uniform and homogenous dispersion of PXC into the host polymer as an aggregation of the
drug was not observed. This could be ascribed to the relative low drug loading employed in this study.

3.5

Effects of drug loading on the mechanical properties of 3D printed
stents

After previous tests confirmed a successful drug-incorporation into PCL, PXC-integration was investigated if it
evokes considerable effects on the mechanical properties of the 3D printed stents. Multiple studies have underlined
the importance and influence of the mechanical properties on the therapeutic efficacy of stents [233-235]. All
samples were printed with same configurations from all three materials: 32 mm length, 4 mm diameter, T-wave
atterned. In addition, care was taken that printed stents obtained the same weight. Thus, alterations of the
mechanical properties amongst stents of different materials can be traced back directly to the altered chemical
composition. The response of the samples to axial and radial compression in a 20-cyclic test method was
investigated in order to obtain the mechanical properties. Results for the axial compression tests are displayed in
figure 25.
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Figure 25. Axial compression data of PCL and PCL-PXC stents. A) Mid-test procedure. (B-D) Axial
compression graphs for PCL, PCL-PXC 1 % and PCL-PXC 5 %. Results reveal higher stability towards
longitudinal compression of the PXC-incorporated, however associated with a higher degree of deformation of the
polymer chains.

All graphs show the typical large hysteresis in the first test cycle due to primary deformation of the polymer chains
[236]. Stents printed from pure PCL (figure 25B) experienced up to ~ 0.71 (± 0.08) N compression force, whilst 1
and 5 % incorporated stents (figure 25C and D) took up to ~ 1.13 (± 0.17) and ~ 1.15 (± 0.10) N respectively.
Force softening occurred for all samples equally, however for the drug-incorporated materials this increased as the
test progressed. This can be observed by the drop of the starting points for each cycle, ending around -0.2 N. Still,
load and unload paths for each measurement cycle did not change significantly for all samples. However, curves
of PCL and the drug loaded samples show different shapes, displayed by a yield point in for pure PCL around 0.35
N, which is absent in figure 25C and D, indicating a decrease of the elasticity in the PXC-composites [237, 238].
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In conclusion, PXC-incorporation increased the ability of the stents fabricated of PCL-PXC composites to obtain
and recover the structure compared to pure PCL-samples, increasing their strength, yet experience higher force
softening. These findings are similar as reported in literature [237, 238]. As mentioned above, to further investigate
the mechanical properties and a potential PXC-incorporation influence on it, circumferential compression was
exposed to the samples. These results are shown in figure 26.
Figure 26. Radial compression data of PCL and PCL-PXC stents. A) Radial compression of a 3D printed stent.

(B-D) Radial compression graphs for PCL, PCL-PXC 1 % and PCL-PXC 5 %. Graphs show an increasing
robustness alongside the stent length potentially due to higher drug-loading.

Similar to the results of the axial compression studies, the initial hysteresis can be observed for radial results
likewise. Further into detail, figure 26B shows that pure PCL-stents require a force of ~ 7.81 (± 0.12) N. On the
other hand, PXC-incorporation has increased the robustness against circumferential compression, as is shown in
figure 26C and 26D given that samples printed from PCL-PXC composites were able to withstand ~ 11.90 (± 0.28)
and ~ 14.90 (± 0.14) N respectively. This implies an increase in the strength of the 1 % and 5 % drug-loaded
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samples by 52 % and 91 % respectively and resembles studies published referring to properties changes of
polymers induced by filler incorporation [239, 240]. Minor force softening occurred for all samples, supported by
some variations in the load and unload paths during the tests. Noticeable is the similar trend for all materials,
suggesting again that the observed differences are due to the incorporation of PXC. Compression experiments
revealed an apparent influence of the drug-incorporation on the host polymer PCL, resulting in an increased
strength and resistance towards applied mechanical stress, yet also a reduction of its elasticity. Table 5 summarizes
the mechanical properties of the axial and radial compression tests of PCL and PCL-PXC loaded stents.
Table 5. Mechanical compression properties of PCL and PCL-PXC loaded stents. Overview of the results for
T-waved stents printed from pristine PCL and loaded with PXC.
Mechanical test

Axial compression

Radial compression

Maximum force

Strain

[N]

[cm]

PCL

0.71 (± 0.08)

4

PCL-PXC 1%

1.13 (± 0.17)

4

PCL-PXC 5%

1.15 (± 0.10)

4

PCL

7.81 (± 0.12)

2

PCL-PXC 1%

11.90 (± 0.28)

2

PCL-PXC 5%

14.90 (± 0.14)

2

Sample
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Tensile properties of pure PCL and both drug-loaded composites were examined to further characterize mechanical
properties of the stents [241]. Samples were stretched at constant speed until breakage occurred. Figure 27 shows
the findings of these measurements.

Figure 27. Tensile test results of PCL and PCL-PXC stents. A) Tensile test performed on a 3D printed stent.
(B-D) Tensile charts for PCL, PCL-PXC 1 % and PCL-PXC 5 %.

Figure 27B shows the results for PCL-stents, which took up to ~ 1.91 (± 0.27) N force at a strain of
16.6 (± 0.77) mm until first stents struts broke and ultimate stent fracture at 22.62 (± 1.21) mm. Samples printed
from PCL-PXC 1 % (figure 27C) however displayed first fracturing at ~ 6.38 (± 0.31) N and 16.03 (± 0.63) mm
stretching, for 5 % incorporated PCL (figure 27D) on the other hand at ~ 5.20 (± 0.34) N and 14.01 (± 0.57) mm.
Subsequently, figure 27C shows final stretching of the stent at ~ 3.18 (± 0.25) N until breakage at
37.48 (± 1.01) mm, higher maximum lengthening compared with results obtained for PCL-PXC 5 %, which
strained at ~ 2.79 (± 0.47) N until 24.94 (± 1.17) mm. Whilst the results for the PCL-PXC composites resemble
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published findings in literature, pure PCL-stents should possess increased strain and therefore experience higher
elongation at break as the test progresses [228, 242, 243]. Potentially, non-uniform and irregular print of these
PCL-stents and therefore weak connection points of the stent struts could be a reason for the minor strain compared
to samples printed from the composites. Drug-incorporation increased the stiffness of PCL, which explains why
samples made from the PCL-PXC 5 % composite broke earlier compared to the lesser loaded blend, though as
well the higher force those composites can take until first struts rupture. Results of the tensile tests are summarized
in table 6.
Table 6. Tensile test results of PCL and PCL-PXC loaded stents. Overview of the tensile tests results for stents
made from different drug-loadings compared to pristine PCL.
Mechanical test

Tensile test

3.6

Maximum force

Maximum strain

[N]

[mm]

PCL

1.91 (± 0.27)

22.62 (± 1.21)

PCL-PXC 1%

6.38 (± 0.31)

37.48 (± 1.01)

PCL-PXC 5%

5.20 (± 0.34)

24.94 (± 1.17)

Sample

Drug-elution studies of 3D printed stents

After basic properties of the ink materials and 3D printed structures were examined, the final part of this project
was to characterise the drug release profiles of 3D printed PCL-PXC stents. It is highly important that stents
possess the ability to deliver pharmacological agents to the stented area in order to improve the therapeutic
efficiency [244]. We chose PXC, an anti-proliferative drug that has shown to effectively reduce the rate of in-stent
restenosis [113, 114], to be incorporated into PCL. Preliminary drug-elution studies in pure PBS showed
precipitation of the drug, indicating a saturation of the drug in the release medium and therefore impairment of the
elution rate. Due to its inferior solubility, Tween-20 as surfactant was added to improve the drug solubility in the
release medium, a procedure previously established for drug-elution studies of PXC [114]. Elution studies are
presented in figure 28, and the total drug-loading of the stents in table 7.
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Figure 28. Release profiles of the PCL-PXC 3D printed stents over 21 days. (A) Cumulative and (B) percentage
drug-release. Cumulative release was normalised using the average stent weight. Obtained profiles resemble zero
order release still after 21 days, suggesting a potential long-term drug-elution.
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Table 7. Total drug-loading of the 3D printed stents.
Stent
weight

Theoretical
total drug
amount

Drug amount
measured
(10 % of stock)

Drug amount
calculated
(100 %)

Efficiency

Average

[mg]

[µg]

[µg]

[µg]

%

[µg]

1

29.8

298.3

28.5

284.9

95.5

2

30.2

302.3

29.3

292.9

96.9

3

29.8

297.7

28.1

280.8

94.3

1

18.4

921.9

87.1

871.2

94.5

2

18.1

903.9

82.6

826.0

91.4

3

17.9

894.5

82.5

824.5

92.2

PCL-PXC 5 % PCL-PXC 1 %

Sample

286.2
(± 6.2)

840.6
(± 26.5)

From day one onwards, both samples elute PXC constantly. Clearly, samples from 5 % loaded PCL elute more
PXC as a result of it higher drug loading. PXC solution showed a decline in concentration of eluted drug depending
on the type of vials used in the release study. [245]. Thus, storing in glass vials tends to yield a lower PXC
concentration compared to using polypropylene vials. Further, during HPLC examination, multiple peaks have
been detected, indicating potential existence of intermediates or decomposition of PXC formed in solution, which
has already been reported in literature [245, 246].
Interesting as well is the percentage release of PXC, which can be observed in figure 28B. After 21 days, samples
printed from PCL-PXC 1 % and 5%-incorporated PCL eluted 2.8 % and 2.0 % of their total drug-loading
respectively. These values might indicate a long-term drug-elution compared with published data of PXC release
of ~ 80 % after 21 days [192]. Most data in the literature are based on dissolution of polymer-PXC coatings and
featured a burst-release at the beginning of the release study[190-193], which did not occur for our results as
displayed in figure 28. For systems involving hydrophobic drug embedded in a hydrophobic matrix, it is possible
that the higher drug loaded system displayed slower percentage release, especially at the early stage. This is likely
due to the fact that drug release starts with hydration and dissolution of surface available drug. Increasing drug
loading does not necessarily improve the amount of drug available on the surface. In summary, we successfully
introduced a drug-elution feature to 3D printed stents with different loadings of PXC.
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4.

Conclusion

AM already proved itself to be a promising manufacturing technique for medical applications over the past decades

[6, 247]. This project investigated AM as an effective method for design and fabrication of polymeric stents,
addressing the need of CVS to optimize their performance: drug-elution during degradation. Hence, the presented
work demonstrates that basic printing protocols were established, stents of different patterns were designed and
manufactured, mechanical properties were evaluated and lastly, a successful drug-elution capability was
demonstrated.
Three general patterns were found to reoccur in literature and commercially available stents as designs: rhombus,
triangle-wave and sinusoidal-like. These designs were recreated using CAD software and programming and
protocols were established for stent printing. To address the drug-eluting feature, PXC as an anti-proliferative
agent was incorporated in 1 % and 5 % loading in the host polymer PCL. Stents were successfully printed from
these materials and characterized by investigating their mechanical responses to stress. Consequently, the influence
of PXC-incorporation on the properties of 3D printed stents was measured – valuable data for DES drafting. The
drug-incorporation resulted in an increased strength and resistance of PCL towards applied mechanical stress, yet
also a reduced elasticity. At last, drug-delivery capability was successfully established, and elution profiles were
estimated, which so far has not been published in literature, since most drug-incorporated polymers are coated
onto a polymeric or metallic stent base. In terms of 3D printing of stents, literature does not report any studies on
the printing from drug-incorporated PCL – especially not with PXC – promising that we potentially established a
new paradigm for 3D printing of DES.
Using AM, an immense freedom is given to the user. Being able to choose the material, stent design, size and
thickness, pharmacological agent, drug-incorporation and therefore its eluting-patterns – all underline the
advantages of 3D printing by manufacturing a patient specifically tailored CVS. This work sets a foundation for
upcoming projects to continue the validation of AM, which has the potential to be the next state-of-the-art
fabrication technique for stents.
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Although basic protocols for 3D printing of biodegradable drug-eluting stents were achieved, future work can
improve this project. With the use of AM, many characteristics of the printed models can be further improved. For
example, reducing product fabrication time while maintaining or even improving product quality is definitely
something to be considered in the future.
Depending on the molecular weight of PCL, its degradation time is estimated to range between 2 to 4 years [248,
249]. However, suggested duration for DES to be applied lies within 6 to 12 months, in which the majority of
harmful cardiac events or ISR may occur [250-252]. As a result, future attempts should focus on the utilization –
or even development – of biocompatible and resorbable polymers that are suitable for stent printing, with a
degradation rate that corresponds with the ideal application time. A likely candidate could be poly-L-lactic acid
(PLLA), which has already been used as clinical assessed stent material [253]. A wide range of potential materials
are available for medical purposes alongside PLLA [254]. Particularly assessing and modifying their properties in
terms of printability are important steps towards development of 3D printed polymeric stents.
Optimising stent and properties represent an important direction for future work. Stent design and strut thicknesses
have direct influence on post-operative outcomes. Studies based on computational fluid dynamic (CFD)
examinations indicated that smaller strut thicknesses are linked to fewer incidents of ISR [153, 255, 256]. Thus,
investigating the shear-stress introduced by the stent design and strut thicknesses via CFD could provide important
insight into the stent development. The diameter of the stents printed in this work was 4 mm. However, considering
that stents will be inflated or expanded after implantation, the original diameter should be > 0.5 mm [257, 258].
The focus of this work was to investigate the development of polymer-based stents with different configurations
via 3D printing. Improving the resolution of the stents and reducing their diameter should be investigated in future
studies. For that reason, assessing the mechanical properties of 3D printed stents under simulated in-use condition
is critical. It is essential to set up experiments that can simulate the implantation process of stents and then the
local in vivo environment of implanted stents.
The mechanical tester and the clamps used in this work to measure the axial mechanical properties are not designed
for tubular structures. Therefore, stents needed to be prepared by covering their ends with cross-linked silicone to
prevent fraction by the clamps. Nevertheless, this introduces uncertain inaccuracies to all measurements, which
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could be obviated through development of suitable clamps for tubular structures. The mechanical properties of the
stents need also to be assessed after inflation to reproduce and simulate the in vivo situation after stent implantation.
Whilst PXC has already been used as pharmaceutical agent in angioplasty stenting, research shows that other drugs
are alternatives to be applied via DES, moreover PXC possesses side effects, being its dose-limiting toxicity among
others [187, 259]. Accordingly, developing and investigating incorporations of alternative drug payloads may
underline the evaluation of 3D printing of DES. Thipparaboina et al. reviewed the dual-drug eluting feature for
CVS, which are capable of including a second drug, enhancing the therapeutic performance for atherosclerosis
treatment by combining for example anti-restenosis with pro-healing agents [260]. Combinations of PXC with
another drug applied by DES have already been reported to increase the post-angioplasty outcome by decreasing
the rate of ISR and thrombotic incidents [261-263]. Keeping the advantages and the freedom of capabilities of AM
in mind, a dual-drug-eluting 3D printed stent could tackle multiple issues at once. Particularly ability to distribute
multiple drugs in a spatially controlled manner to realise targeted release profile of each drug is an important
advantage of AM. An example is shown in appendix V. Nevertheless, the drugs chosen must maintain their
stability and efficacy when subjected to the conditions occurring during 3D printing, such as the print temperature,
extrusion pressure among others.
As mentioned in 3.2.9 and 3.2.10, drug-elution studies were performed in PBS (pH 7.4), placed in a shaking bath
at 37 ˚C. However, this procedure does not reflect the in vivo situation of a continuous, pulsing blood flow. Neubert
et al. established and investigated a flow-through cell as a new tool to examine the drug-elution performance of
stents, which is able to simulate the natural blood flow by circulating PBS (pH 7.4) with a flow rate of 35 mL/min
and simultaneously the balloon-catheter implantation into an artificial blood vessel, represented by calcium
alginate hydrogel [264-266]. Based on this idea, we designed such a vessel simulating flow-through cell with
Autodesk Inventor 2018. Yet, due to time restrictions, we were not able to execute this procedure for drug-elution
studies. Please refer to appendix VII for the engineering drawings of the designed cell.
At last, ultimate evaluation of a 3D printed DES would be a direct comparison of its properties and capabilities
with an already commercially available stent. Those stents already went through decades of characterisations,
evaluations and clinical trials meaning an immense amount of information is available and therefore highly
valuable for the evolution of stents.
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Appendices
Appendix I – T-Stent G-code
G-code to print T-stents. Highlighted (yellowish) are adjustable parameters to print stent with desired
configuration.

%
G49
G40
G17
G80
G90
#1=20
#2=2
#3=[#2/#1]
#4=40
#5=6
#6=[[#4-[#2*#5]]/[#5-1]]
#7=8
#8=[360/#7]
#9=[2*#1]
#10=[#8/#9]
#11=0
#12=0
#13=0
#14=1
#15=0
#16=0
#17=0
G0X0Y0Z0F2000
M98 P1000 L#5
M98 P1004 L[#5-1]
M9
G0Z5
M30
O1000
G92 A0
#15=0
#12=[#2*#14+#6*[#14-1]]
G0X#12
M98 P1001 L#7
G0Y0
#14=[#14+1]
M09
M99

(Number of Increments)
(Ring Width)
(X Increment Distance)
(Length of construct)
(Number of Rings)
(Ring Separation, Length-RW*#rings)
(Number of V's)
(Width of V's in degrees)
(Increments per V)
(A Increment)
(Current V)
(Current X)
(X loop counter)
(Current Ring)
(Current A)
(SECOND A INCREMENT)

(MAKE THE RINGS)

(MAKE A RING)
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O1001
M08
M07
M98 P1002 L#1
M98 P1003 L#1
M99

(MAKE A V)

O1002
G1X[#12-#3]Y0A[#15+#10] (X Move Negative)
#15=[#15+#10]
#12=[#12-#3]
M99
O1003
G1X[#12+#3]Y0A[#15+#10] (X Move Positive)
#15=[#15+#10]
#12=[#12+#3]
M99

%

O1004
M9
G92A0
G0Z2
G0X[#17+#2]A0F100
G0Z0
M07
M08
G1X[#17+#2+#6]f100
M9
G0Z2
G0X[#17+#2]A180
G0Z0
M08
M07
G1X[#17+#2+#6]F100
M9
G0Z2
G0A90
#17=[#17+#6+#2]
M99

(CONNECTORS)
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Appendix II – SEM images
As mentioned in Materials & Methods, chapter 3.2.6: Scanning electron microscope imaging, SEM images were
edited to improve the visibility of the scale bars. All original images obtained are subsequently listed in figure 29
to 34.

Figure 29. Original SEM image of a single T-wave ring.
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Figure 30. Original SEM image of a T-wave ring surface.
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Figure 31. Original SEM image of break edge of a 3D printed stent.

3D printed degradable stents with controlled drug delivery capabilities

80

Appendices

Figure 32. Original SEM surface images of a PCL stent.
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Figure 33. Original SEM surface images of a PCL-PXC 1 % stent.

3D printed degradable stents with controlled drug delivery capabilities

82

Appendices

Figure 34. Original SEM surface images of a PCL-PXC 5 % stent.
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Appendix III – HPLC calibration
In order to measure the amount of a specific compound using HPLC method, it is necessary to establish a
calibration curve by preparing and measuring standards of known concentration of said compound. The protocol
we used to establish the calibration curve for PXC is listed in table 8. Final plotted calibration curve is displayed
in figure 35.
Table 8. Standards concentration to establish HPLC calibration curve. Solvent used was a mixture of
CH3CN/milliQ-H2O in a ratio of 45:55.
Standard

m(PXC)

Concentration

Previous solution

Solvent

[ng/mL]

[mL]

[mL]

Stock

100000

-

-

S1

[µg]
1 mg in
1 mL CH3CN
50

50000

50

950

S2

25

25000

500

500

S3

12.5

12500

500

500

S4

6.25

6250

500

500

S5

3.13

3125

500

500

S6

1.56

1562.50

500

500

S7

0.78

781.25

500

500

S8

0.39

390.63

500

500

S9

0.20

195.31

500

500

S10

010

97.66

500

500

S11

0.049

48.83

500

500

S12

0.024

24.41

500

500

S13

0.012

12.21

500

500

S14

0.0061

6.10

500

500

S15

0.0031

3.05

500

500
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Figure 35. Calibration curve for HPLC measurements. Established curve possesses a linearity of
0.99965 and therefore a high accuracy to measure PXC (R2: regression coefficient).
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Appendix IV – Elution studies time marks
Listed in table 9 are the time marks when the medium was taken and replaced by fresh medium.
Table 9. Time marks of release medium extraction. Studies for both PCL-PXC composites were taken at same
time.
Date

Time

Hours

Days

START: 03.02.18

17:00 PM

0

1

04.02.2018

19:00 PM

26

2

05.02.2018

13:45 PM

44.75

3

06.02.2018

12:00 PM

67

4

07.02.2018

16:10 PM

95.17

5

08.02.2018

16:30 PM

119.50

6

09.02.2018

17:00 PM

144

7

10.02.2018

17:00 PM

168

8

11.02.2018

17:00 PM

192

9

12.02.2018

17:00 PM

216

10

13.02.2018

17:30 PM

240.50

11

14.02.2018

19:45 PM

264.50

12

15.02.2018

19:00 PM

288

13

16.02.2018

19:00 PM

312

14

17.02.2018

19:00 PM

336

15

18.02.2018

19:00 PM

360

16

19.02.2018

19:30 PM

384.50

17

21.02.2018

19:00 PM

408.50

18

22.02.2018

19:00 PM

432.50

19

23.02.2018

19:30 PM

457

20

24.02.2018

19:00 PM

481

21

25.02.2018

20:00 PM

506
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Appendix V – Dual-material 3D printed stent
AM gives the user the ability to design and edit models in different configurations. As previously mentioned, new
studies face towards combinations of drugs for atherosclerosis treatment, applied by a stent. To show that 3D
printing is capable to fabricate such a dual-material stent, we dyed PCL which hence should mimic either another
polymer or a different incorporated drug. Printed stents of different shapes are displayed in figure 36.

Figure 36. Dual-material 3D printed stents. Blue-coloured parts simulate drug-containing polymers,
underlining the ability and advantage of AM to choose the drug-concentration in a fabricated stent.

PCL was dissolved in chloroform and dyed by adding blue food-colouring. After 24 h, the blue solution has been
transferred to cold n-hexane, leading to precipitation of the dyed polymer. Remaining solvent was removed
through vacuum drying.
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Appendix VI – Vessel-simulating flow-through cell
Based on the invented vessel-simulating flow-through cell by Neubert et al. [264], we designed a similar cell
prototype for a potential use for drug-elution studies of stents with Autodesk Invention 2018 software, consisting
of four parts: main cell, sealing lid, inner disk and inlet/outlet nozzle tip (figure 37 to 40 respectively).

Figure 37. Engineering drawing of designed flow-through main cell.

Figure 38. Engineering drawing of cell sealing lid.
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Figure 39. Drawing of inserted disk to separate the hydrogel from glass beads.

Figure 40. Drawing of nozzle tip for the in- and outlet of the circulating fluid.
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